Previous 10 | Next 10 |
Summary Integra's fourth quarter results were in-line but still lackluster, with just 3% organic revenue growth. Management is still in a building/reinvestment phase ahead of revenue acceleration, but there are multiple products that could achieve market differentiation and drive real r...
Integra LifeSciences Holdings Corporation (IART) Q4 2022 Earnings Conference Call February 22, 2023 08:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President & Chief Executive Officer Jeffrey Mosebrook - SVP, Chief A...
The following slide deck was published by Integra LifeSciences Holdings Corporation in conjunction with their 2022 Q4 earnings call. For further details see: Integra LifeSciences Holdings Corporation 2022 Q4 - Results - Earnings Call Presentation
Integra LifeSciences Holdings press release ( NASDAQ: IART ): Q4 Non-GAAP EPS of $0.94 beats by $0.04 . Revenue of $398M (-1.8% Y/Y) misses by $0.57M . Outlook: For the full-year 2023, the Company expects revenues to be in a range of $1,602 million to $1,620 million, r...
PRINCETON, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2022, consistent with its preliminary financial results announced on January 10, 2023 and Januar...
Integra LifeSciences Holdings ( NASDAQ: IART ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, before market open. The consensus EPS Estimate is $0.90 (+7.1% Y/Y) and the consensus Revenue Estimate is $398.57M (-1.7% Y/Y). Over the last 2 years, IART ...
PRINCETON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter 2022 financial results on Wednesday, February 22, 2023, prior to the market open. In conjunction with ...
Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The SMID Cap Growth Strategy targets attractively p...
Integra LifeSciences ( NASDAQ: IART ) has entered into an accelerated share repurchase agreement with Goldman Sachs. The agreement enables the firm to buyback $150M of its outstanding shares of common stock, par value $0.01 per share. The transactions are expected to be completed ...
Integra LifeSciences ( NASDAQ: IART ) sees its Q4 2022 adjusted EPS coming in between $0.92 and $0.96 per share. That compares to $0.84 for the same period in 2021. For full-year 2022, adjusted EPS is expected to be $3.34 to $3.38 . In 2021, m the figure was $3.18. Earlier...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
21.25%Change Percent:
Integra LifeSciences Holdings Corporation Company Name:
IART Stock Symbol:
NASDAQ Market:
2024-07-29 18:00:04 ET Ryan Zimmerman from BTIG issued a price target of $22.00 for IART on 2024-07-29 16:12:00. The adjusted price target was set to $22.00. At the time of the announcement, IART was trading at $25.42. The overall price target consensus is at $51.17 with...
2024-07-29 17:15:01 ET BTIG analyst issues SELL recommendation for IART on July 29, 2024 04:12PM ET. IART was trading at $25.42 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 2 - Hold, 1 - Sell ...
2024-07-29 12:23:00 ET Shares of Integra Lifesciences (NASDAQ: IART) were sinking 15.5% as of 11 a.m. ET on Monday. The decline came after the medical technology company announced its second-quarter results before the market opened. Integra reported Q2 revenue of $418.2 million,...